IMA ImageneBio Inc.

Price (delayed)

$5.75

Market cap

$64.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.24

Enterprise value

-$8.78M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral ...

Highlights
The EPS has soared by 67% year-on-year and by 56% since the previous quarter
The debt has dropped by 63% year-on-year and by 19% since the previous quarter
The equity has contracted by 7% from the previous quarter but it has grown by 4.3% YoY
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The gross profit has shrunk by 100% QoQ and by 100% YoY

Key stats

What are the main financial stats of IMA

IMA stock price

How has the ImageneBio stock price performed over time
Intraday
5.5%
1 week
-2.95%
1 month
0.61%
1 year
-64.24%
YTD
-16.67%
QTD
15%

Financial performance

How have ImageneBio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$55.93M
Net income
-$45.07M
Gross margin
N/A
Net margin
N/A
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year
The gross profit has shrunk by 100% QoQ and by 100% YoY
The operating income has dropped by 86% year-on-year and by 15% since the previous quarter
The net income has dropped by 62% year-on-year

Price vs fundamentals

How does IMA's price correlate with its fundamentals

Growth

What is ImageneBio's growth rate over time

Valuation

What is ImageneBio stock price valuation
P/E
N/A
P/B
0.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 67% year-on-year and by 56% since the previous quarter
IMA's price to book (P/B) is 51% lower than its 5-year quarterly average of 1.0 and 2% lower than its last 4 quarters average of 0.5
The equity has contracted by 7% from the previous quarter but it has grown by 4.3% YoY
The revenue has dropped by 100% since the previous quarter and by 100% year-on-year

Efficiency

How efficient is ImageneBio business performance
IMA's return on invested capital has dropped by 134% year-on-year and by 19% since the previous quarter
ImageneBio's return on equity has increased by 43% YoY and by 13% QoQ
ImageneBio's return on assets has increased by 13% QoQ and by 2.5% YoY

Dividends

What is IMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMA.

Financial health

How did ImageneBio financials performed over time
IMA's quick ratio is up by 47% from the previous quarter and by 36% YoY
The current ratio has grown by 47% from the previous quarter and by 38% YoY
The debt is 98% smaller than the equity
The debt to equity has plunged by 67% YoY
The debt has dropped by 63% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.